Trial Profile
An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs AV 101 (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- 31 Mar 2020 Results assessing whether 4-Cl-KYN has rapid antidepressant effects in individuals with treatment-resistant depression (TRD) published in the International Journal of Neuropsychopharmacology
- 04 Dec 2019 Status changed from recruiting to completed.
- 29 Jun 2017 According to a VistaGen Therapeutics media release, the company expects top-line results from the study during the first half of 2018.